Patents by Inventor Natalie Fursov

Natalie Fursov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Anti-CD27 Antibodies
    Publication number: 20240141055
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: June 29, 2023
    Publication date: May 2, 2024
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Neutralizing human anti-CD27 antibodies
    Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Human Anti-CD27 Antibodies
    Publication number: 20200277393
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies
    Patent number: 10689453
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: June 23, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ST2L antagonists and methods of use
    Patent number: 10450377
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 22, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Methods of Inhibiting Activity Using Anti-CD27 Antibodies
    Publication number: 20190248910
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies
    Patent number: 10301392
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 28, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ST2L antagonists and methods of use
    Patent number: 9951137
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: April 24, 2018
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Methods of Inhibiting Activity Using Anti-CD27 Antibodies
    Publication number: 20170320957
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 16, 2017
    Publication date: November 9, 2017
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Nucleic acid molecules encoding anti-CD27 antibodies
    Patent number: 9683046
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 20, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ST2L Antagonists and Methods of Use
    Publication number: 20170066831
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: November 12, 2015
    Publication date: March 9, 2017
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
    Patent number: 9212227
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 15, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Human Anti-CD27 Antibodies, Methods and Uses
    Publication number: 20150299330
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: July 2, 2015
    Publication date: October 22, 2015
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Human anti-CD27 antibodies, methods and uses
    Patent number: 9102737
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 11, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ST2L antibody antagonists
    Patent number: 9090694
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 28, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • ST2L Antagonists and Methods of Use
    Publication number: 20130336980
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 19, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • ST2L Antagonists and Methods of Use
    Publication number: 20130287777
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • HUMAN ANTI-CD27 ANTIBODIES, METHODS AND USES
    Publication number: 20130243795
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 19, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ST2L
    Patent number: 7879978
    Abstract: Isolated polynucleotides encoding Macaca fascicularis ST2L (Cyno ST2L), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: February 1, 2011
    Assignee: Centocor Ortho Biotech, Inc.
    Inventors: Adam Cotty, Natalie Fursov, Michael Naso
  • Macaca fascicularis ST2L
    Publication number: 20100247442
    Abstract: Isolated polynucleotides encoding Macaca fascicularis ST2L (Cyno ST2L), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.
    Type: Application
    Filed: March 31, 2009
    Publication date: September 30, 2010
    Inventors: Adam Cotty, Natalie Fursov, Michael Naso